Calavo Growers’ fourth quarter earnings fall short
Santa Paula-based Calavo Growers missed analyst projections on its fourth-quarter earnings. Calavo Growers, which is known for its avocado production, reported on Dec. 29 a profit of 28 cents per share, missing Wall Street’s projection of 46 cents per share. Calavo Growers stock ended the day at $49.51 per share, down $1.14. The company posted Read More →
Sientra faces disclosure lawsuits
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Freska buys Oceanside avocado packing plant
Oxnard-based Freska Produce International has purchased an avocado packer, Harvest Time Produce of Oceanside, the company announced in a news release Dec. 17. The move by Freska, which already has a Mexican avocado program, will allow the company known for mangoes to use the Oceanside packing plant to become a year-round provider of avocados. Terms Read More →
Amgen increases dividend to $1 per share
Amgen increased its yearly dividend 27 percent this year to $1 per share. Previously, the dividend had been 79 cents per share for the Thousand Oaks-based biotech giant. Shares jumped after news of the 27-cent dividend broke. The announcement was made just after the markets closed at 1:11 p.m. Amgen closed the trading day up Read More →
Ceres plans to raise $6.7 million through public stock offering Dec. 17
Ceres, a Thousand Oaks-based agriculture-biotechnology company, priced shares at 40 cents each on Dec. 15 for its follow-on public offering on Dec. 17. Ceres plans to raise $6.7 million through the offering, which will be comprised of 600,000 shares of common stock, 6,460 shares of preferred stock convertible into 16,150,000 shares of common stock, and Read More →
Amgen reacquires rights to sell 3 drugs worldwide
Amgen reacquired all rights to sell three drugs worldwide on Dec. 14. The Thousand Oaks-based biotech giant said it reacquired the rights to Prolia, Vectibix and Xgeva in 48 ccountries from British pharmaceutical company GlaxoSmithKline. The agreement includes large countries like Australia, China and Brazil. Prolia is designed to raise bone density in people with Read More →
